Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for Neural Target Engagement in Adolescents With ASD
NCT06826326Phase 2Enrolling by invitation
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Escitalopram oxalate oral solution in Autism Spectrum Disorder (ASD). Started Apr 2025; status: enrolling by invitation.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06826326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826326.